Paper40944149
Gut Dysbiosis and Plasma Trimethylamine Oxide Are Associated with Subclinical Coronary Atherosclerosis in Obese Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease.
Islam K and 6 others. Nutrients, 2025. Cited by 2 papers, by iCite.
Cite this record
ConductScience Library. Gut Dysbiosis and Plasma Trimethylamine Oxide Are Associated with Subclinical Coronary Atherosclerosis in Obese Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease. Papers, record 40944149. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40944149
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Gut Dysbiosis and Plasma Trimethylamine Oxide Are Associated with Subclinical Coronary Atherosclerosis in Obese Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease.
- PubMed
Topics14
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Methylamines | Major topic |
| Dysbiosis | Major topic |
| Gastrointestinal Microbiome | Major topic |
| Obesity | Major topic |
| Coronary Artery Disease | Major topic |
| Fatty Liver | Major topic |
| Humans | |
| Male | |
| Female | |
| Middle Aged | |
| Cross-Sectional Studies | |
| Aged | |
| Body Mass Index | |
| Feces |
Source PubMed
Grants3
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| B36G660010 | Program Management Unit for Human Resources & Institutional Development, Research and Innovation (PMU-B) | PubMed | ||
| N84H670030 | National Research Council of Thailand | PubMed | ||
| Second Century Fund | PubMed |
Source PubMed
References58
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 35863685 | Comparative Burden of Metabolic Dysfunction in Lean NAFLD vs Non-lean NAFLD - A Systematic Review and Meta-analysis. | Clin Gastroenterol Hepatol | 2023 | https://conductscience.org/library/papers/35863685 | PubMed |
| 2 | 30179269 | Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. | Hepatology | 2019 | https://conductscience.org/library/papers/30179269 | PubMed |
| 3 | 34294762 | Gut microbiota-generated metabolite, trimethylamine-N-oxide, and subclinical myocardial damage: a multicenter study from Thailand. | Sci Rep | 2021 | https://conductscience.org/library/papers/34294762 | PubMed |
| 4 | 37591886 | Gut microbiota-derived tryptamine and phenethylamine impair insulin sensitivity in metabolic syndrome and irritable bowel syndrome. | Nat Commun | 2023 | https://conductscience.org/library/papers/37591886 | PubMed |
| 5 | 22992469 | Chronic kidney disease alters intestinal microbial flora. | Kidney Int | 2013 | https://conductscience.org/library/papers/22992469 | PubMed |
| 6 | 36453081 | Obesity in South and Southeast Asia-A new consensus on care and management. | Obes Rev | 2023 | https://conductscience.org/library/papers/36453081 | PubMed |
| 7 | 34445037 | Potential Benefits of Probiotics and Prebiotics for Coronary Heart Disease and Stroke. | Nutrients | 2021 | https://conductscience.org/library/papers/34445037 | PubMed |
| 8 | 39040013 | Exploring the Gut Microbiota: Key Insights Into Its Role in Obesity, Metabolic Syndrome, and Type 2 Diabetes. | J Clin Endocrinol Metab | 2024 | https://conductscience.org/library/papers/39040013 | PubMed |
| 9 | 25767908 | Development and validation of a simple UHPLC-MS/MS method for the simultaneous determination of trimethylamine N-oxide, choline, and betaine in human plasma and urine. | J Pharm Biomed Anal | 2015 | https://conductscience.org/library/papers/25767908 | PubMed |
| 10 | 30082863 | Development of a gut microbe-targeted nonlethal therapeutic to inhibit thrombosis potential. | Nat Med | 2018 | https://conductscience.org/library/papers/30082863 | PubMed |
| 11 | 32413340 | Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis. | Lancet Gastroenterol Hepatol | 2020 | https://conductscience.org/library/papers/32413340 | PubMed |
| 12 | 2402637 | Structure and function of lipopolysaccharide binding protein. | Science | 1990 | https://conductscience.org/library/papers/2402637 | PubMed |
| 13 | 37364790 | A multisociety Delphi consensus statement on new fatty liver disease nomenclature. | J Hepatol | 2023 | https://conductscience.org/library/papers/37364790 | PubMed |
| 14 | 32986965 | Intestinal barrier dysfunction as a therapeutic target for cardiovascular disease. | Am J Physiol Heart Circ Physiol | 2020 | https://conductscience.org/library/papers/32986965 | PubMed |
| 15 | 17259367 | Development of a semiquantitative degenerate real-time pcr-based assay for estimation of numbers of butyryl-coenzyme A (CoA) CoA transferase genes in complex bacterial samples. | Appl Environ Microbiol | 2007 | https://conductscience.org/library/papers/17259367 | PubMed |
| 16 | 37015876 | Ruminococcus gnavus: friend or foe for human health. | FEMS Microbiol Rev | 2023 | https://conductscience.org/library/papers/37015876 | PubMed |
| 17 | 38265508 | Non-alcoholic fatty liver disease in patients with morbid obesity: the gut microbiota axis as a potential pathophysiology mechanism. | J Gastroenterol | 2024 | https://conductscience.org/library/papers/38265508 | PubMed |
| 18 | 18574091 | Coronary artery calcification compared with carotid intima-media thickness in the prediction of cardiovascular disease incidence: the Multi-Ethnic Study of Atherosclerosis (MESA). | Arch Intern Med | 2008 | https://conductscience.org/library/papers/18574091 | PubMed |
| 19 | 33129264 | Gut microbiome profiling of a rural and urban South African cohort reveals biomarkers of a population in lifestyle transition. | BMC Microbiol | 2020 | https://conductscience.org/library/papers/33129264 | PubMed |
| 20 | 33764858 | The role of short-chain fatty acids in the interplay between gut microbiota and diet in cardio-metabolic health. | Gut Microbes | 2021 | https://conductscience.org/library/papers/33764858 | PubMed |
Cited by4
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 2 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42780431 | Gut microbiota composition in responders vs. non-responders with hepatocellular carcinoma under ICI therapy: a systematic review and meta-analysis. | Front Med (Lausanne) | 2026 | https://conductscience.org/library/papers/42780431 | PubMed |
| 42541628 | MASLD and Cardiovascular Risk: Mechanisms and Implications for Clinical Practice. | Curr Hypertens Rep | 2026 | https://conductscience.org/library/papers/42541628 | PubMed |
| 42509691 | Dissecting the Gut Microbiota-metabolite-coronary Atherosclerosis Axis: Evidence from Two-sample Mendelian Randomization. | Endocr Metab Immune Disord Drug Targets | 2026 | https://conductscience.org/library/papers/42509691 | PubMed |
| 42026467 | Functional remodeling of the gut microbiome and metabolome in primary idiopathic male infertility. | BMC Microbiol | 2026 | https://conductscience.org/library/papers/42026467 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/40944149
GET https://conductscience.org/api/papers/v1/40944149/references?page=2